Harvard Just Mapped Every Drug That Fights Aging—and They're Already on Shelves

A groundbreaking 2026 study from Harvard and Northeastern University mapped 6,442 approved drugs against the hallmarks of aging using network medicine. Researchers discovered 370 candidates already on pharmacy shelves - including aspirin, rapamycin, and dasatinib - that may slow aging at the molecular level. This isn't hype. It's a computational prediction engine that could reshape longevity science by repurposing existing medicines rather than waiting for new ones. Discover how network pharmacology reveals which approved drugs target aging pathways, why single-target thinking fails, and what this means for the future of geroscience and clinical longevity interventions. Subscribe to Tomorrow Unveiled for insights into the science shaping our future. #DrugRepurposing #LongevityResearch #NetworkMedicine #Aging #Geroscience #HallmarksOfAging #DrugDiscovery #HealthScience 📑 Chapters: 00:00:00 Intro 00:01:27 The Pile of Genes Becomes a Map 00:03:02 Treating Aging Like a Disease 00:04:50 Reading the Whole Pharmacy 00:06:19 The Direction Problem 00:08:00 The Invisible Drugs 00:09:42 Does the Map Predict Anything? 00:11:33 The Honest Ledger 00:13:09 What a Map Changes 00:14:35 Closing